fbpx

Day

February 11, 2020
CAMBRIDGE, Mass., Feb. 11, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today commenced its previously announced rights offering to raise gross proceeds of $30.0 million (the “Rights Offering”). Under the terms of the...

Nyheder

New test exposes dangerous moles
14. February 2020
Asthma is programmed early in life
7. February 2020
A female dog may well be the answer
24. January 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge